scholarly journals Solitary Metastasis in the Mediastinal Lymph Node After Radical Nephrectomy for Clear Cell Renal Cell Carcinoma: A Case Report and Literature Review

2020 ◽  
Vol 10 ◽  
Author(s):  
Hang Lin ◽  
Heng Zhang ◽  
Yuanda Cheng ◽  
Chunfang Zhang
Keyword(s):  
Renal Cell Carcinoma ◽  
Lymph Node ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Mediastinal Lymph Node ◽  
Cell Renal Cell Carcinoma ◽  
Posterior Mediastinal

BackgroundRenal cell carcinoma can metastasize to virtually any anatomical site throughout the body, especially the lung, bone, lymph nodes, liver, and brain. However, it is extremely rare for renal cell carcinoma to metastasize solely to the mediastinal lymph node more than 15 years after radical nephrectomy.Case PresentationThe case we present here is that of a 50-year-old Chinese male with an isolated posterior mediastinal lymph node metastasis of clear cell renal cell carcinoma 16 years after radical nephrectomy. However, based on imaging examination, the mass was clinically misdiagnosed as Castleman’s disease before operation. Following surgical excision of the mass, it was finally judged to be a metastasis from clear cell renal cell carcinoma according to the patient’s medical history and immunohistochemical findings. Currently, there is no clinical or radiological finding the recurrence of metastasis after 10 months of follow-up.ConclusionWe report a case of solitary metastasis in the posterior mediastinal lymph node 16 years after radical nephrectomy for clear cell renal cell carcinoma. Given the long disease-free interval between primary renal cell carcinoma to isolated mediastinal lymph node metastasis, it is important to conduct a lifelong regular follow-up, including thoracic computed tomography. In addition, surgical resection remains the best method of treatment for mediastinal lymph node metastases from clear cell renal cell carcinoma if the metastatic lesion is limited.

scholarly journals Comparative effectiveness of adrenal sparing radical nephrectomy and non-adrenal sparing radical nephrectomy in clear cell renal cell carcinoma: Observational study of survival outcomes

2015 ◽  
Vol 9 (9-10) ◽  
pp. 583 ◽  
Author(s):  
Gregory J. Nason ◽  
Leon G. Walsh ◽  
Ciaran E. Redmond ◽  
Niall P. Kelly ◽  
Barry B. McGuire ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Observational Study ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Risk Groups ◽  
Survival Outcomes ◽  
Cell Renal Cell Carcinoma

Introduction: We compare the survival outcomes of patients with clear cell renal cell carcinoma (RCC) treated with adrenal sparing radical nephrectomy (ASRN) and non-adrenal sparing radical nephrectomy (NASRN).Methods: We conducted an observational study based on a composite patient population from two university teaching hospitals who underwent RN for RCC between January 2000 and December 2012. Only patients with pathologically confirmed RCC were included. We excluded patients undergoing cytoreductive nephrectomy, with loco-regional lymph node involvement. In total, 579 patients (ASRN = 380 and NASRN = 199) met our study criteria. Patients were categorized by risk groups (all stage, early stage and locally advanced RCC). Overall survival (OS) and cancer-specific survival (CSS) were analyzed for risk groups. Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazards regression.Results: The median follow-up was 41 months (range: 12–157). There were significant benefits in OS (ASRN 79.5% vs. NASRN 63.3%; p = 0.001) and CSS (84.3% vs.74.9%; p = 0.001), with any differences favouring ASRN in all stage. On multivariate analysis, there was a trend towards worse OS (hazard ratio [HR] 1.759, 95% confidence interval [CI] 0.943–2.309, p = 0.089) and CSS (HR 1.797, 95% CI 0.967–3.337, p = 0.064) in patients with NASRN (although not statistically significant). Of these patients, only 11 (1.9%) had adrenal involvement.Conclusions: The inherent limitations in our study include the impracticality of conducting a prospective randomized trial in this scenario. Our observational study with a 13-year follow-up suggests ASRN leads to better survival than NASRN. ASRN should be considered the gold standard in treating patients with RCC, unless it is contraindicated.

scholarly journals PD12-03 ASSOCIATION OF PARTIAL AND RADICAL NEPHRECTOMY ON SURVIVAL IN YOUNG PATIENTS WITH NON-CLEAR CELL RENAL CELL CARCINOMA

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Kristian Stensland ◽  
Jared Schober ◽  
David Canes ◽  
Navneet Ramesh ◽  
Brendan Waldoch ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Young Patients ◽  
Cell Renal Cell Carcinoma

scholarly journals Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma

2018 ◽  
Vol 5 (4) ◽  
pp. 6-13 ◽  
Author(s):  
Juan Chipollini ◽  
Mounsif Azizi ◽  
Charles C Peyton ◽  
Dominic H Tang ◽  
Jasreman Dhillon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Type I ◽  
Cell Renal Cell Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Papillary Type

The purpose of this study was to assess the prognostic value of programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ?1% of staining. Histopathological characteristics and oncological outcomes were correlated to PD-L1 expression. Cancer-specific survival (CSS) and recurrence-free survival (RFS) stratified by PD-L1 status were estimated using the Kaplan–Meier method. Median age was 58 years and median follow-up was 40 months. Non-ccRCC subtypes included sarcomatoid (n = 9), rhabdoid (n = 6), medullary (n = 2), Xp11.2 translocation (n = 2), collecting duct (n = 1), papillary type I (n = 11), and papillary type II (n = 14). PD-L1 positivity was noted in nine (20%) patients. PD-L1 positivity was significantly associated with higher Fuhrman nuclear grade (P = 0.048) and perineural invasion (P = 0.043). Five-year CSS was 73.2 and 83% for PD-L1 positive and negative tumors, respectively (P = 0.47). Five-year RFS was 55.6 and 61.5% for PD-L1 positive and negative tumors, respectively (P = 0.58). PD-L1 was expressed in a fifth of non-ccRCC cases and was associated with adverse histopathologic features. Expression of biomarkers such PD-L1 may help better risk-stratify non-ccRCC patients to guide treatment decisions and follow-up strategies.

scholarly journals MP36-05 CHANGES IN PATTERN OF RECURRENCE OVER TIME AFTER RADICAL NEPHRECTOMY IN PATIENTS WITH LOCALIZED CLEAR CELL RENAL CELL CARCINOMA

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Kenji Tanabe ◽  
Kazutaka Saito ◽  
Kazuaki Nakagomi ◽  
Chizuru Arisawa ◽  
Tetsuro Tsukamoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Over Time ◽  
Pattern Of Recurrence

scholarly journals 1095: Association of Abnormal Preoperative Laboratory Values with Survival Following Radical Nephrectomy for Clinically Confined Clear Cell Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 352-352
Author(s):  
James S. Magera ◽  
Bradley C. Leibovich ◽  
Christine M. Lohse ◽  
Shomik Sengupta ◽  
John C. Cheville ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Laboratory Values
Sign in / Sign up

Export Citation Format

Share Document